CJC-1295 With DAC

Kuvaus

CJC-1295 with DAC (Drug Affinity Complex), also known as DAC:GRF, is a synthetic tetrasubstituted analog of growth hormone-releasing hormone (GHRH) modified with a Drug Affinity Complex to bind to albumin in the bloodstream, dramatically extending its half-life to approximately 6-8 days after a single injection. This allows for prolonged, continuous stimulation of the pituitary gland, leading to sustained increases in endogenous growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels—often maintaining elevated concentrations for up to a week or more, in contrast to the shorter, pulsatile release seen with CJC-1295 No DAC (Mod GRF 1-29). Research and anecdotal reports suggest potential benefits including increased lean muscle mass and strength, accelerated recovery from training or injuries, enhanced fat metabolism (particularly visceral and stubborn fat), improved sleep quality, better bone density, joint health support, and overall metabolic improvements when used in controlled research settings or wellness protocols. Typical researched dosing involves subcutaneous injections of 1-2mg once or twice weekly (far less frequent than No DAC versions), sometimes stacked with growth hormone secretagogues like Ipamorelin for amplified effects without excessive prolactin or cortisol elevation. While preclinical studies and some observational data highlight these regenerative and performance-enhancing properties, CJC-1295 with DAC is not FDA-approved for any human therapeutic use as of 2026—it remains an investigational research peptide, flagged by the FDA for inclusion on lists of bulk substances that may present significant safety risks, including reports of elevated heart rate, systemic vasodilatory reactions, immunogenicity concerns (potential for life-threatening anaphylaxis or other immune responses), and other adverse events. Many experts and sources recommend avoiding CJC-1295 with DAC due to its continuous GH elevation profile, which can lead to greater side effects such as water retention, joint pain or stiffness, carpal tunnel-like symptoms, numbness/tingling, insulin resistance, increased body temperature, headaches, mood swings, anxiety, nausea, flu-like symptoms, or more pronounced fatigue compared to pulsatile alternatives. It is prohibited by WADA for athletes and carries risks of hormonal imbalances or unknown long-term effects from prolonged supraphysiological GH/IGF-1 exposure. Side effects often appear more persistent or severe with the DAC version due to its extended activity and inflexible dosing. Never use without supervision from a qualified healthcare provider experienced in peptides, as self-administration risks contamination, improper dosing, adverse reactions, or legal issues. Prioritize evidence-based approaches for fitness, recovery, or anti-aging goals—consult a professional to assess suitability, source from reputable compounding pharmacies if considered under guidance (though availability is restricted), and stay informed on regulatory or emerging research developments. CJC-1295 with DAC is not a substitute for proven medical treatments or lifestyle interventions.